1.Application of aptamers for assessment of vaccine efficacy.
Soo Young YOON ; Grace GEE ; Kee Jong HONG ; Sang Hwan SEO
Clinical and Experimental Vaccine Research 2017;6(2):160-163
Assessing antigen concentration of vaccine is essential step in determining the quality of the vaccine prior to vaccination. After vaccination, vaccine-induced antibody titer should also be measured to verify the vaccine efficacy. Since conventional assay used for vaccine concentrations and induced Ab-titers is antibody-based enzyme-linked immunosorbent assay, the assay inevitably brings drawbacks of antibody such as high cost for production, limited stability, and inconsistent quality between lot-to-lots. Aptamer is single-stranded nucleic acid having three-dimensional structure and has features overcoming limitations of antibody. This review will briefly introduce the features of aptamer and potential of aptamer-based system for evaluation of vaccine efficacy.
Antibodies
;
Enzyme-Linked Immunosorbent Assay
;
Vaccination
;
Vaccines
2.Microneedles: quick and easy delivery methods of vaccines.
Ki Mun KWON ; Su Min LIM ; Seulgi CHOI ; Da Hee KIM ; Hee Eun JIN ; Grace JEE ; Kee Jong HONG ; Joo Young KIM
Clinical and Experimental Vaccine Research 2017;6(2):156-159
Vaccination is the most efficient method for infectious disease prevention. Parenteral injections such as intramuscular, intradermal, and subcutaneous injections have several advantages in vaccine delivery, but there are many drawbacks. Thus, the development of a new vaccine delivery system has long been required. Recently, microneedles have been attracting attention as new vaccination tools. Microneedle is a highly effective transdermal vaccine delivery method due to its mechanism of action, painlessness, and ease of use. Here, we summarized the characteristics of microneedles and the possibilities as a new vaccine delivery route.
Communicable Diseases
;
Injections, Subcutaneous
;
Methods*
;
Vaccination
;
Vaccines*
3.Surveillance and compensation claims for adverse events following immunization from 2011 to 2016 in the Republic of Korea.
Min Kyung KIM ; Yeon Kyeong LEE ; Tae Eun KIM ; Insik KONG ; Hyeon Jong YANG ; Eun Sook SUH
Clinical and Experimental Vaccine Research 2017;6(2):146-155
PURPOSE: In recent years, research on reported adverse events following immunization (AEFI) and claims filed for compensation has been lacking. We reviewed reported AEFIs and compensation claims in Korea from 2011 to 2016. MATERIALS AND METHODS: We listed all of the AEFI registered in the Integrated Management System of Disease and Public Health and reviewed the list of claims filed and serious AEFIs reported from 2011 to 2016. RESULTS: An average of 278 AEFI cases was reported annually from 2011 to 2016. Of these, 31 deaths were reported. However, there was no association found between these deaths and vaccinations when evaluating vaccine lot, reviewing autopsies, and considering underlying diseases. AEFI reporting rate was as high as 20.8 cases for bacillus Calmette–Guérin (BCG) vaccine, 7.3 cases for 23-valent pneumococcal polysaccharide vaccine (PPV23), and 5.4 cases for human papillomavirus vaccine per 100,000 vaccination doses in 2016. Of the 469 total cases that claimed vaccine injury compensation from 2011 to 2016, the BCG vaccine was most commonly involved, with 235 cases (50%), followed by influenza vaccine and PPV23, with 90 and 55 cases, respectively. Of these cases, 96% of BCG-related AEFI were compensated, while only 31% and 49% of AEFI following influenza and PPV23 vaccination, respectively, were compensated. Common characteristics of uncompensated cases included the elderly subjects, receiving influenza vaccine, having underlying disease, or a very short time interval between vaccination and symptoms. CONCLUSION: We have maintained vaccine safety management system through both rapid response to serious AEFI and vaccine injury compensation in order to sustain public trust in the National Immunization Program.
Aged
;
Autopsy
;
Bacillus
;
BCG Vaccine
;
Compensation and Redress*
;
Drug-Related Side Effects and Adverse Reactions
;
Government Programs
;
Humans
;
Immunization Programs
;
Immunization*
;
Influenza Vaccines
;
Influenza, Human
;
Korea
;
Pneumococcal Vaccines
;
Public Health
;
Public Health Surveillance
;
Republic of Korea*
;
Safety Management
;
Vaccination
4.Preferential production of IgM-secreting hybridomas by immunization with DNA vaccines coding for Ebola virus glycoprotein: use of protein boosting for IgG-secreting hybridoma production.
Si Hyeong LEE ; Baek Sang HAN ; Jongseon CHOE ; Jeong Im SIN
Clinical and Experimental Vaccine Research 2017;6(2):135-145
PURPOSE: The goal of this study was to investigate the utility of DNA vaccines encoding Ebola virus glycoprotein (GP) as a vaccine type for the production of GP-specific hybridomas and antibodies. MATERIALS AND METHODS: DNA vaccines were constructed to express Ebola virus GP. Mice were injected with GP DNA vaccines and their splenocytes were used for hybridoma production. Enzyme-linked immunosorbent assays (ELISAs), limiting dilution subcloning, antibody purification methods, and Western blot assays were used to select GP-specific hybridomas and purify monoclonal antibodies (MAbs) from the hybridoma cells. RESULTS: Twelve hybridomas, the cell supernatants of which displayed GP-binding activity, were selected by ELISA. When purified MAbs from 12 hybridomas were tested for their reactivity to GP, 11 MAbs, except for 1 MAb (from the A6-9 hybridoma) displaying an IgG2a type, were identified as IgM isotypes. Those 11 MAbs failed to recognize GP. However, the MAb from A6-9 recognized the mucin-like region of GP and remained reactive to the antigen at the lowest tested concentration (1.95 ng/mL). This result suggests that IgM-secreting hybridomas are predominantly generated by DNA vaccination. However, boosting with GP resulted in greater production of IgG-secreting hybridomas than GP DNA vaccination alone. CONCLUSION: DNA vaccination may preferentially generate IgM-secreting hybridomas, but boosting with the protein antigen can reverse this propensity. Thus, this protein boosting approach may have implications for the production of IgG-specific hybridomas in the context of the DNA vaccination platform. In addition, the purified monoclonal IgG antibodies may be useful as therapeutic antibodies for controlling Ebola virus infection.
Animals
;
Antibodies
;
Antibodies, Monoclonal
;
Antibody Formation
;
Blotting, Western
;
Clinical Coding*
;
DNA*
;
Ebolavirus*
;
Enzyme-Linked Immunosorbent Assay
;
Glycoproteins*
;
Hemorrhagic Fever, Ebola
;
Hybridomas*
;
Immunization*
;
Immunoglobulin G
;
Immunoglobulin M
;
Mice
;
Vaccination
;
Vaccines, DNA*
5.A genetically modified rabies vaccine (ERAGS) induces protective immunity in dogs and cattle.
Dong Kun YANG ; Ha Hyun KIM ; Seung Heon LEE ; Woong Ho JEONG ; Dongseop TARK ; In Soo CHO
Clinical and Experimental Vaccine Research 2017;6(2):128-134
PURPOSE: The current live attenuated rabies vaccine must be replaced with a safer vaccine based on the ERAGS strain to prevent rabies in South Korea. We evaluated the safety and immunogenicity of a new strain in dogs and cattle. MATERIALS AND METHODS: The ERAGS strain, featuring two mutations altering two amino acids in a glycoprotein of rabies virus, was propagated in NG108-15 cells. We lyophilized the virus in the presence of two different stabilizers to evaluate the utilities of such preparations as novel rabies vaccines for animals. To explore safety and immunogenicity, dogs and cattle were inoculated with the vaccine at various doses via different routes and observed daily for 8 weeks post-inoculation (WPI). Immunogenicity was evaluated using a fluorescent antibody virus neutralization test or enzyme-linked immunosorbent assay. RESULTS: The two different stabilizers did not differ greatly in terms of maintenance of virus viability in accelerated stability testing. No clinical signs of rabies developed in dogs or cattle inoculated with the vaccines (10(7.0) FAID₅₀/mL). Dogs and cattle inoculated intramuscularly with 10(5.0) FAID₅₀/mL exhibited virus neutralization assay titers of 4.6 IU/mL and 1.5 to 0.87 IU/mL at 4 WPI, respectively. All control animals remained rabies virus–seronegative throughout, confirming that no contact transmission occurred between vaccinated and control animals. CONCLUSION: Our findings indicate that the new rabies vaccine is safe and immunogenic in dogs and cattle.
Amino Acids
;
Animals
;
Cattle*
;
Dogs*
;
Enzyme-Linked Immunosorbent Assay
;
Glycoproteins
;
Korea
;
Microbial Viability
;
Neutralization Tests
;
Rabies Vaccines*
;
Rabies virus
;
Rabies*
;
Vaccines
6.Static model simulation for routine mumps vaccination in Japan: with a result of mumps-related complications in a Japanese community hospital.
Taito KITANO ; Masayuki ONAKA ; Mariko ISHIHARA ; Atsuko NISHIYAMA ; Naoki HASHIMOTO ; Sayaka YOSHIDA
Clinical and Experimental Vaccine Research 2017;6(2):120-127
PURPOSE: Mumps vaccine has not been included in the routine national immunization program in Japan, leading to low vaccine coverage rates and periodic epidemics approximately every 5 years. Our hospital (a secondary community hospital in Japan) experienced an increased number of mumps-related complications with a nationwide epidemic in 2016. Using previously reported data and mumps-related cases in our hospital, we estimated the cost-effectiveness of routine mumps vaccination in Japan with a static model using current epidemiologic data. MATERIALS AND METHODS: With a decision tree flowchart of mumps infection and adverse events, we estimated the burden of mumps-related complications in our hospital for 5 years, and calculated the current annual national burden. Finally, we compared the current burden and assumptive burden of the stable state after routine vaccination in Japan using a static model. RESULTS: The cost-benefit ratios with sensitivity analysis were 3.69 (1.08-9.52) and 6.84 (1.51-23.73) in independent inoculation and simultaneous inoculation, respectively, from a social perspective in addition to an annual gain of 9,487 (3,227-14,659) quality adjusted life years. CONCLUSION: We contributed additional evidence in terms of cost-effectiveness that routine mumps vaccination should be introduced in Japan with simultaneous inoculation.
Asian Continental Ancestry Group*
;
Cost-Benefit Analysis
;
Decision Trees
;
Hospitals, Community*
;
Humans
;
Immunization Programs
;
Japan*
;
Mumps Vaccine
;
Mumps*
;
Quality-Adjusted Life Years
;
Software Design
;
Vaccination*
7.Mass vaccination has led to the elimination of rabies since 2014 in South Korea.
Dong Kun YANG ; Ha Hyun KIM ; Kyoung Ki LEE ; Jae Young YOO ; Hong SEOMUN ; In Soo CHO
Clinical and Experimental Vaccine Research 2017;6(2):111-119
PURPOSE: Rabies is one of the most fatal diseases, but it is 100% preventable in animals by vaccination. In this study, we present the epidemiological features of, and national preventive measures against, rabies in Korea. MATERIALS AND METHODS: Data related to rabies and the population density of raccoon dogs in Korea were collected from the Animal and Plant Quarantine Agency, the Korean Centers for Disease Control and Prevention, and the National Institute of Environmental Research. Rabies diagnosis was confirmed with a fluorescent antibody test using brain samples of animals in accordance with the procedures described by the World Organization for Animal Health. Serological assays for dogs and cattle were conducted using the fluorescent antibody virus neutralization test. RESULTS: From 1993 to 2016, a total of seven human rabies cases and 437 animal rabies cases in five different species were reported. An increase in the distribution of bait vaccine seemed to be related to a dramatic decrease in rabies prevalence in endemic rabies regions. Two Korean provinces and the capital city, Seoul, were involved in rabies outbreaks. Korean rabies strains are most closely related to the eastern Chinese strain belonging to the Arctic-like lineage. The yearly seropositive rates ranged from 50.4% to 81.2% in dogs and from 25% to 60.5% in cattle residing in endemic rabies regions. CONCLUSION: This study indicates that national preventive measures, including mass vaccination and distribution of bait vaccines, have contributed to a substantial decrease in the number of rabies cases in Korea.
Animals
;
Asian Continental Ancestry Group
;
Brain
;
Cattle
;
Centers for Disease Control and Prevention (U.S.)
;
Diagnosis
;
Disease Eradication
;
Disease Outbreaks
;
Dogs
;
Epidemiology
;
Humans
;
Korea*
;
Mass Vaccination*
;
Neutralization Tests
;
Plants
;
Population Density
;
Prevalence
;
Quarantine
;
Rabies*
;
Raccoon Dogs
;
Seoul
;
Vaccination
;
Vaccines
8.Animal models for dengue vaccine development and testing.
Woonsung NA ; Minjoo YEOM ; Il Kyu CHOI ; Heejun YOOK ; Daesub SONG
Clinical and Experimental Vaccine Research 2017;6(2):104-110
Dengue fever is a tropical endemic disease; however, because of climate change, it may become a problem in South Korea in the near future. Research on vaccines for dengue fever and outbreak preparedness are currently insufficient. In addition, because there are no appropriate animal models, controversial results from vaccine efficacy assessments and clinical trials have been reported. Therefore, to study the mechanism of dengue fever and test the immunogenicity of vaccines, an appropriate animal model is urgently needed. In addition to mouse models, more suitable models using animals that can be humanized will need to be constructed. In this report, we look at the current status of model animal construction and discuss which models require further development.
Animals*
;
Climate Change
;
Dengue Virus
;
Dengue*
;
Endemic Diseases
;
Humans
;
Korea
;
Mice
;
Models, Animal*
;
Vaccines
9.Recent outbreaks of highly pathogenic avian influenza viruses in South Korea.
Hye Kwon KIM ; Dae Gwin JEONG ; Sun Woo YOON
Clinical and Experimental Vaccine Research 2017;6(2):95-103
Outbreaks of H5 highly pathogenic avian influenza viruses (HPAIVs) have caused economic loss for the poultry industry and posed a threat to public health. In South Korea, novel reassortants of HPAIVs such as H5N6 and H5N8 had been circulating in poultry. Here, we will discuss the identity of recent novel reassortants of Korean H5 HPAIVs and the recent advances in vaccine development, which will be useful for controlling HPAIV transmission in poultry and for effectively preventing future epidemics and pandemics.
Animals
;
Disease Outbreaks*
;
Epidemiology
;
Influenza in Birds*
;
Korea*
;
Pandemics
;
Poultry
;
Public Health
;
Vaccines
10.The significance of avian influenza virus mouse-adaptation and its application in characterizing the efficacy of new vaccines and therapeutic agents.
Won Suk CHOI ; Khristine Kaith S. LLOREN ; Yun Hee BAEK ; Min Suk SONG
Clinical and Experimental Vaccine Research 2017;6(2):83-94
Due to the increased frequency of interspecies transmission of avian influenza viruses, studies designed to identify the molecular determinants that could lead to an expansion of the host range have been increased. A variety of mouse-based mammalian-adaptation studies of avian influenza viruses have provided insight into the genetic alterations of various avian influenza subtypes that may contribute to the generation of a pandemic virus. To date, the studies have focused on avian influenza subtypes H5, H6, H7, H9, and H10 which have recently caused human infection. Although mice cannot fully reflect the course of human infection with avian influenza, these mouse studies can be a useful method for investigating potential mammalian adaptive markers against newly emerging avian influenza viruses. In addition, due to the lack of appropriate vaccines against the diverse emerging influenza viruses, the generation of mouse-adapted lethal variants could contribute to the development of effective vaccines or therapeutic agents. Within this review, we will summarize studies that have demonstrated adaptations of avian influenza viruses that result in an altered pathogenicity in mice which may suggest the potential application of mouse-lethal strains in the development of influenza vaccines and/or therapeutics in preclinical studies.
Animals
;
Host Specificity
;
Humans
;
Influenza A virus
;
Influenza in Birds*
;
Influenza Vaccines
;
Methods
;
Mice
;
Orthomyxoviridae
;
Pandemics
;
Serial Passage
;
Vaccination
;
Vaccines*
;
Virulence